Heard

Sign InJoin Heard

Legislative record

SB 274STATE · VirginiaIntroduced

Prescription Drug Affordability Board; established, drug cost affordability review, report.

Voted 4/17/2024

Summary

Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between January 1, 2025, and January 1, 2028.The bill requires the Board to report its findings and recommendations to the General Assembly twice annually, beginning on July 1, 2025, and December 31, 2025. Provisions of the bill shall apply to state-sponsored and state-regulated health plans and health programs and obligate such policies to limit drug payment amounts and reimbursements to an upper payment limit amount set by the Board, if applicable, following an affordability review. The bill specifies that Medicare Part D plans shall not be bound by such decisions of the Board.The bill also requires the nonprofit organization contracted by the Department of Health to provide prescription drug price transparency to provide the Board access to certain data reported by manufacturers. The bill has a delayed effective date of January 1, 2025, and is identical to HB 570.

Digest published by the state legislature, retrieved via Open States. Heard is not affiliated with either.

Bill text

The full text of this bill isn't on Heard yet. The official documents are linked below.

Roll-call record

How representatives voted

177 yea·102 nay·6 other

Docket history

Action history

  1. 4/17/2024Requires 2/3 members present
  2. 4/17/2024Passed in enrolled form rejected (21-Y 18-N)
  3. 4/8/2024Vetoed by Governor
  4. 3/11/2024Governor's Action Deadline 11:59 p.m., April 8, 2024
  5. 3/11/2024Enrolled Bill Communicated to Governor on March 11, 2024
  6. 3/2/2024Signed by President
  7. 2/28/2024Signed by Speaker
  8. 2/28/2024Impact statement from DPB (SB274ER)
  9. 2/28/2024Bill text as passed Senate and House (SB274ER)
  10. 2/28/2024Enrolled